SI-BONE is turning a once-forgotten joint into a high-margin sacropelvic platform—now reaching self-funding profitability, but racing the clock on reimbursement and bundling threats.
Overview
SI-BONE (SIBN) is positioned as a high-quality small-cap MedTech growth story transitioning from a perceived single-product SI joint company into a broader **“sacropelvic solutions” platform** spanning degenerative SI fusion, adult spinal deformity fixation, and pelvic trauma. The thesis is supported by (1) category leadership with a defensible clinical moat—**>130,000 procedures** and **135+ peer-reviewed publications** including Level 1 RCTs, (2) a 2025 financial inflection to **positive adjusted EBITDA and operating cash flow**, materially reducing dilution/financing risk, and (3) reimbursement/regulatory advantages, notably **Granite’s FDA Breakthrough Device Designation** and resulting **NTAP/TPT** benefits that support premium pricing and ~80% gross margins. FY25 revenue guidance rose to **$198–$200M** (18–20% growth), gross margins remained ~79–80%, and the balance sheet is strong with **~$110M net cash**. The report recommends **Overweight/Buy** with a **$26 12-month target**, while emphasizing key risks: NTAP/TPT expiration (2027–2028), a CCO transition in early 2026, insider selling optics, and competitive bundling pressures from diversified spine giants.